Chemical formula: C₂₃H₁₇FN₆O Molecular mass: 412.428 g/mol PubChem compound: 25145656
Capmatinib is indicated for:
Population group: only adults (18 years old or older)
Capmatinib as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Capmatinib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
